0.10Open0.10Pre Close0 Volume20 Open Interest25.00Strike Price0.00Turnover238.99%IV189.50%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0578Delta0.0235Gamma86.70Leverage Ratio-0.0134Theta0.0002Rho5.02Eff Leverage0.0024Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet